Search

A NEW CLASS of biopharmaceuticals based on RNA interference (RNAi) may lie on the horizon. Identified only five years ago, RNAi is not yet fully understood, but there are already [...]

CAMBRIDGE, Mass. -- Alnylam Pharmaceuticals Inc. and Cubist Pharmaceuticals Inc. confirm that a midstage study of their experimental drug for a respiratory infection has met its major objective. The biopharmaceutical [...]

The gene-silencing technique called RNA interference has moved a step closer to becoming a viable therapeutic approach. Scientists at Alnylam Pharmaceuticals in Cambridge, used RNAi in monkeys to silence the gene for apolipoprotein B (ApoB), a protein involved in cholesterol metabolism, and it was observed that a single injection of a short interfering RNA reduced the level of ApoB gene in the liver.